Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
Mineralys Therapeutics (NASDAQ: MLYS) has scheduled a conference call and webinar for March 10, 2025, at 8:00 AM ET to announce topline results from two pivotal trials: Launch-HTN and Advance-HTN.
The trials evaluated lorundrostat, a highly selective aldosterone inhibitor, for treating uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). The Launch-HTN trial tested lorundrostat as an add-on therapy to existing prescribed background treatment of 2-5 antihypertensive medications, while Advance-HTN evaluated it as an add-on to a standardized background treatment of 2-3 anti-hypertensive medications.
Mineralys Therapeutics (NASDAQ: MLYS) ha programmato una conference call e un webinar per il 10 marzo 2025, alle 8:00 AM ET, per annunciare i risultati preliminari di due studi clinici fondamentali: Launch-HTN e Advance-HTN.
Gli studi hanno valutato lorundrostat, un inibitore dell'aldosterone altamente selettivo, per il trattamento dell'ipertensione non controllata (uHTN) o dell'ipertensione resistente (rHTN). Lo studio Launch-HTN ha testato lorundrostat come terapia aggiuntiva al trattamento di base già prescritto di 2-5 farmaci antipertensivi, mentre Advance-HTN lo ha valutato come aggiunta a un trattamento di base standardizzato di 2-3 farmaci antipertensivi.
Mineralys Therapeutics (NASDAQ: MLYS) ha programado una conferencia telefónica y un seminario web para el 10 de marzo de 2025, a las 8:00 AM ET, para anunciar los resultados preliminares de dos ensayos clínicos fundamentales: Launch-HTN y Advance-HTN.
Los ensayos evaluaron lorundrostat, un inhibidor de la aldosterona altamente selectivo, para el tratamiento de la hipertensión no controlada (uHTN) o hipertensión resistente (rHTN). El ensayo Launch-HTN probó lorundrostat como terapia complementaria al tratamiento de base ya prescrito de 2-5 medicamentos antihipertensivos, mientras que Advance-HTN lo evaluó como complemento a un tratamiento de base estandarizado de 2-3 medicamentos antihipertensivos.
미네랄리스 테라퓨틱스 (NASDAQ: MLYS)는 2025년 3월 10일 오전 8시(ET)에 컨퍼런스 콜 및 웨비나를 개최하여 두 가지 주요 임상 시험인 Launch-HTN 및 Advance-HTN의 주요 결과를 발표할 예정입니다.
이 시험에서는 조절되지 않는 고혈압(uHTN) 또는 내성 고혈압(rHTN) 치료를 위해 매우 선택적인 알도스테론 억제제인 로룬드로스타트를 평가했습니다. Launch-HTN 시험은 2-5개의 항고혈압 약물에 대한 기존 처방 치료에 추가 요법으로 로룬드로스타트를 시험했으며, Advance-HTN은 2-3개의 항고혈압 약물에 대한 표준화된 배경 치료에 추가 요법으로 평가했습니다.
Mineralys Therapeutics (NASDAQ: MLYS) a prévu une conférence téléphonique et un webinaire pour le 10 mars 2025, à 8h00 ET, afin d'annoncer les résultats préliminaires de deux essais cliniques majeurs : Launch-HTN et Advance-HTN.
Les essais ont évalué lorundrostat, un inhibiteur de l'aldostérone hautement sélectif, pour le traitement de l'hypertension non contrôlée (uHTN) ou de l'hypertension résistante (rHTN). L'essai Launch-HTN a testé lorundrostat comme thérapie additionnelle au traitement de base déjà prescrit de 2 à 5 médicaments antihypertenseurs, tandis qu'Advance-HTN l'a évalué comme ajout à un traitement de base standardisé de 2 à 3 médicaments antihypertenseurs.
Mineralys Therapeutics (NASDAQ: MLYS) hat eine Telefonkonferenz und ein Webinar für den 10. März 2025, um 8:00 Uhr ET, angesetzt, um die vorläufigen Ergebnisse aus zwei entscheidenden Studien bekannt zu geben: Launch-HTN und Advance-HTN.
Die Studien bewerteten lorundrostat, einen hochselektiven Aldosteronhemmer, zur Behandlung von unkontrollierter Hypertonie (uHTN) oder resistenter Hypertonie (rHTN). Die Studie Launch-HTN testete lorundrostat als Zusatztherapie zu einer bestehenden Verschreibung von 2-5 blutdrucksenkenden Medikamenten, während Advance-HTN es als Zusatz zu einer standardisierten Basisbehandlung von 2-3 blutdrucksenkenden Medikamenten bewertete.
- None.
- None.
RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar to announce topline results from its Launch-HTN and Advance-HTN pivotal trials on Monday, March 10, 2025, at 8:00 a.m. ET.
The Launch-HTN trial evaluated the efficacy and safety of lorundrostat, a highly selective aldosterone inhibitor, for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) as an add-on therapy to an existing, prescribed background treatment of two to five antihypertensive medications.
The Advance-HTN trial evaluated the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN when used as an add-on therapy to a standardized background treatment of two or three anti-hypertensive medications.
| Monday, March 10th@ 8:00 a.m. ET | |
| Domestic: | 1-877-704-4453 |
| International: | 1-201-389-0920 |
| Webcast: | Link |
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
When will Mineralys Therapeutics (MLYS) announce the Launch-HTN and Advance-HTN trial results?
What is the purpose of the Launch-HTN trial for MLYS's lorundrostat?
How does the Advance-HTN trial differ from Launch-HTN for MLYS's hypertension treatment?
What conditions is Mineralys Therapeutics (MLYS) targeting with lorundrostat?
